Ipilimumab is a monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), an immune checkpoint protein that inhibits T-cell activity. By blocking CTLA-4, ipilimumab enhances the immune system’s ability to attack cancer cells, making it a type of immune checkpoint inhibitor. It has shown significant efficacy in treating cancers like melanoma, particularly in cases with brain metastases, and is now being explored for other cancers, including glioblastoma (GBM), the mos